News

NICE has developed medical technology guidance on the UroLift system. NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed…

A new understanding of inflammatory bowel diseases has been prompted by the analysis of genetic and clinical data from more than 30,000 patients. This study reveals that genetic factors affect the location of the inflammation in the gut,…

Continence Advisor or Continence Physiotherapist - Do you know who does what? You've probably heard your GP mention Continence Advisors and Continence Physiotherapists before, but do you really know who does what? Although nowadays both…

If you would like to view a helpful video about how pelvic floor muscle exercises can help with SUI, especially after childbirth please click here to view it. Video shown with the permission of Women’s Physiotherapy Services, Cambridge…

NICE have published a guideline on bladder cancer.  This guideline offers evidence-based advice on the diagnosis and management of bladder cancer in adults (18 years and older) referred from primary care with suspected bladder cancer, and…

The results of a clinical study were recently published, looking specifically at the use of anticholinergics (cumulative) and the development of dementia for people over the age of 65. 1   Results from the study showed that the long-term…

Astellas Pharma Europe Ltd. has announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the…

According to study author Prof. James Morris of the Vancouver Cancer Centre at the British Columbia Cancer Agency (BCCA) in Canada, this is the first study to compare the two techniques in the treatment of prostate cancer. The American…

Older women with urinary tract infections who are taking the commonly prescribed antibiotic nitrofurantoin are more likely to experience treatment failure, resulting in a second antibiotic prescription or a hospital visit, than if they…

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab), within their marketing authorisations, as options…